These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Re: "Confounding by indication and channeling over time: the risks of beta2-agonists". Pearce N; Beasley R; Crane J; Burgess C Am J Epidemiol; 1997 Nov; 146(10):885-7. PubMed ID: 9384211 [No Abstract] [Full Text] [Related]
5. International trends in sales of inhaled fenoterol, all inhaled beta-agonists, and asthma mortality, 1970-1992. Lanes SF; Birmann B; Raiford D; Walker AM J Clin Epidemiol; 1997 Mar; 50(3):321-8. PubMed ID: 9120532 [TBL] [Abstract][Full Text] [Related]
6. The use of beta agonists and the risk of death and near death from asthma. Pearce N J Clin Epidemiol; 2009 Jun; 62(6):582-7. PubMed ID: 19422997 [No Abstract] [Full Text] [Related]
7. Beta agonists and asthma mortality: déjà vu. Pearce N; Crane J; Burgess C; Jackson R; Beasley R Clin Exp Allergy; 1991 Jul; 21(4):401-10. PubMed ID: 1680532 [No Abstract] [Full Text] [Related]
8. End of the New Zealand asthma mortality epidemic. Pearce N; Beasley R; Crane J; Burgess C; Jackson R Lancet; 1995 Jan; 345(8941):41-4. PubMed ID: 7799709 [TBL] [Abstract][Full Text] [Related]
9. The saga of the New Zealand asthma mortality epidemic. N Z Med J; 1995 Mar; 108(995):91. PubMed ID: 7661939 [No Abstract] [Full Text] [Related]
10. Withdrawal of fenoterol and the end of the New Zealand asthma mortality epidemic. Beasley R; Pearce N; Crane J; Burgess C Int Arch Allergy Immunol; 1995; 107(1-3):325-7. PubMed ID: 7613161 [TBL] [Abstract][Full Text] [Related]
11. Optical illusions from visual data analysis: example of the New Zealand asthma mortality epidemic. Suissa S; Ernst P J Clin Epidemiol; 1997 Oct; 50(10):1079-88. PubMed ID: 9368515 [TBL] [Abstract][Full Text] [Related]
12. Fenoterol and asthma deaths. Grant IW Thorax; 1998 Jan; 53(1):77. PubMed ID: 9577529 [No Abstract] [Full Text] [Related]
13. Risk of severe life threatening asthma. Barnes NC; Kuitert LM Thorax; 1996 Nov; 51(11):1073. PubMed ID: 8958886 [No Abstract] [Full Text] [Related]
15. Beta 2-agonists and New Zealand asthma mortality. Burgess C; Crane J; Pearce N; Beasley R Lancet; 1991 Apr; 337(8747):982-3. PubMed ID: 1678066 [No Abstract] [Full Text] [Related]
16. Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity. Garrett JE; Lanes SF; Kolbe J; Rea HH Thorax; 1996 Nov; 51(11):1093-9. PubMed ID: 8958891 [TBL] [Abstract][Full Text] [Related]
17. The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Sears MR; Taylor DR Drug Saf; 1994 Oct; 11(4):259-83. PubMed ID: 7848546 [TBL] [Abstract][Full Text] [Related]
18. The use of beta-agonists and the risk of death and near death from asthma. Spitzer WO; Suissa S; Ernst P; Horwitz RI; Habbick B; Cockcroft D; Boivin JF; McNutt M; Buist AS; Rebuck AS N Engl J Med; 1992 Feb; 326(8):501-6. PubMed ID: 1346340 [TBL] [Abstract][Full Text] [Related]
19. The proper role of beta 2-adrenergic agonists in the treatment of children with asthma. Furukawa CT; Kemp JP; Simons FE; Tinkelman DG Pediatrics; 1992 Oct; 90(4):639-40. PubMed ID: 1357623 [No Abstract] [Full Text] [Related]
20. A review of the studies of the asthma mortality epidemic in New Zealand. Beasley R; Burgess C; Crane J; Pearce N Allergy Proc; 1995; 16(1):27-32. PubMed ID: 7768457 [No Abstract] [Full Text] [Related] [Next] [New Search]